Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study

被引：0
|
作者：
Haifer, C. [1 ,2 ]
Srinivasan, A. [3 ,4 ]
Menon, S. [5 ]
An, Y. [9 ]
Picardo, S. [8 ]
Van Langenberg, D.
Begun, J. [8 ,9 ]
Ghaly, S. [1 ]
Thin, L. [6 ,7 ]
机构：
[1] St Vincents Hosp, Melbourne, Vic, Australia
[2] Univ Sydney, Sydney, NSW, Australia
[3] Eastern Hlth, Box Hill, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Royal Perth Hosp, Perth, WA, Australia
[6] Fiona Stanley Hosp, Murdoch, WA, Australia
[7] Univ Western Australia, Perth, WA, Australia
[8] Mater Hosp, Brisbane, Qld, Australia
[9] Univ Queensland, Brisbane, Qld, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
217
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [31] Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease
    Haghnejad, Vincent
    Le Berre, Catherine
    Dominique, Yoann
    Zallot, Camille
    Guillemin, Francis
    Peyrin-Biroulet, Laurent
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (03) : 281 - 288
  • [32] RAPID 30-MINUTE INFLIXIMAB INFUSION PROTOCOLS ARE SAFE AND EFFECTIVE WHEN SWITCHING INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB
    Srinivasan, Ashish
    van Langenberg, Daniel R.
    Haar, Geoffrey
    Miller, Caroline
    Rodrigues, Beverly
    GASTROENTEROLOGY, 2019, 156 (06) : S633 - S634
  • [33] Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
    Milassin, Agnes
    Fabian, Anna
    Molnar, Tames
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [34] Switching of Patients With Inflammatory Bowel Disease From Original Infliximab (Remicade®) to Biosimilar Infliximab (Remsima™) Is Effective and Safe
    Kolar, Martin
    Duricova, Dana
    Bortlik, Martin
    Hruba, Veronika
    Machkova, Nadezda
    Mitrova, Katarina
    Malickova, Karin
    Lukas, Martin
    Lukas, Milan
    GASTROENTEROLOGY, 2016, 150 (04) : S416 - S416
  • [35] Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe
    Kolar, M.
    Duricova, D.
    Brotlik, M.
    Hruba, V.
    Machkova, N.
    Mitrova, K.
    Malickova, K.
    Lukas, M.
    Lukas, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S45 - S46
  • [36] Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study
    Schmitz, E. M. H.
    Boekema, P. J.
    Straathof, J. W. A.
    van Renswouw, D. C.
    Brunsveld, L.
    Scharnhorst, V.
    van de Poll, M. E. C.
    Broeren, M. A. C.
    Derijks, L. J. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (03) : 356 - 363
  • [37] Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study
    Trystram, Noemie
    Abitbol, Vered
    Tannoury, Jenny
    Lecomte, Mahaut
    Assaraf, Julie
    Malamut, Georgia
    Gagniere, Charlotte
    Barre, Amelie
    Sobhani, Iradj
    Chaussade, Stanislas
    Amiot, Aurelien
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (08) : 887 - 899
  • [38] Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
    Fischer, S.
    Mesfin, S.
    Klenske, E.
    Schmitt, H.
    Vitali, F.
    Hirschmann, S.
    Ramming, A.
    Zundler, S.
    Rath, T.
    Krebs, S.
    Doerje, F.
    Uter, W.
    Nagore, D.
    Meyer, S.
    Neurath, M. F.
    Atreya, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S466 - S467
  • [39] Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
    Martinez-Feito, Ana
    Bravo-Gallego, Luz Yadira
    Hernandez-Breijo, Borja
    Diez, Jesus
    Garcia-Ramirez, Laura
    Jaquotot, Marta
    Plasencia-Rodriguez, Chamaida
    Nozal, Pilar
    Mezcua, Araceli
    Martin- Arranz, Maria Dolores
    Pascual-Salcedo, Dora
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [40] Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
    Ana Martínez-Feito
    Luz Yadira Bravo-Gallego
    Borja Hernández-Breijo
    Jesús Diez
    Laura García-Ramirez
    Marta Jaquotot
    Chamaida Plasencia-Rodríguez
    Pilar Nozal
    Araceli Mezcua
    María Dolores Martín- Arranz
    Dora Pascual-Salcedo
    Scientific Reports, 10
12345